NovaWell.
GLP-1 C research vial
Sequence length
37 AA
Molecular weight
~4409 g/mol
Current batch
GLP1C202601
Metabolic · Amylin receptor pharmacology / Metabolic research

GLP-1 C

Long-acting amylin analog (Y1–Y3 amylin receptor agonist)

GLP-1 C (10mg vials)

Sign up for verified researcher access to view pricing, see in-stock quantity, and order at member volume tiers (up to 20% off at 20+ vials).

Sign up to view pricing and order.Verified researchers only. Active immediately on sign-up.
Apply for access →

Specifications

Molecular weight~4409 g/mol
Sequence length37 amino acids
ModificationsN-terminal lysine acylation with C20 (eicosanedioic) fatty diacid via γ-Glu linker; pramlintide-like backbone with key substitutions
Parent receptorAmylin receptors (AMY1R, AMY2R, AMY3R) / calcitonin receptor
AppearanceWhite lyophilized powder
SolubilityBacteriostatic water; sterile water
Storage (lyophilized)-20°C, protected from light
Storage (reconstituted)2–8°C, use within 28 days
Current batch purity99.16% (HPLC) · GLP1C202601

GLP-1 C is the research code NovaWell uses for the long-acting amylin analog known in the published clinical-trial literature as Cagrilintide. The molecule is a non-selective agonist at the amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor. The 37-amino-acid peptide is built on a pramlintide-like backbone with substitutions that improve receptor affinity and physical stability, plus an N-terminal lysine acylation with a C20 fatty diacid via a γ-glutamic acid linker that promotes albumin binding and supports a multi-day plasma half-life consistent with once-weekly subcutaneous dosing in clinical-research settings. The molecule is studied in metabolic research for its effects on satiety signaling, gastric emptying, and energy balance, and is being investigated in combination with the GLP-1 receptor agonist analog described in this catalog as GLP-1 S. NovaWell supplies GLP-1 C as a lyophilized powder in 10 mg vials, third-party tested, for laboratory research use only. Reference to the molecule in published literature does not imply suitability for any human application.

Research Studies

The following studies are summarized for educational purposes only. Reference to clinical-trial literature describes published research findings, not any endorsement of human use of the research-grade compound supplied here.

Research study

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Lau DCW, Erichsen L, Francisco AM, et al. Lancet. 2021;398(10317):2160–2172. View source ↗

Scientific findings

This Phase 2 dose-finding trial randomized 706 adults with body mass index ≥30 (or ≥27 with weight-related comorbidities, without diabetes) across 57 sites in ten countries to once-weekly subcutaneous cagrilintide (0.3, 0.6, 1.2, 2.4, or 4.5 mg), liraglutide 3.0 mg daily, or placebo, over a 26-week treatment period that included up to 6 weeks of dose escalation. At week 26, mean percentage body-weight change was -10.8% at the 4.5 mg cagrilintide dose versus -3.0% with placebo and -9.0% with liraglutide 3.0 mg. Approximately 31% of participants in the 4.5 mg cagrilintide arm achieved ≥15% weight reduction versus 5.2% in placebo. The compound was generally well tolerated; the most common adverse events were gastrointestinal (nausea, decreased appetite) and consistent with the amylin receptor agonist mechanism.

Plain English

A 26-week study tested five different weekly doses of cagrilintide against placebo and against a daily GLP-1 comparator in adults with overweight or obesity. The highest cagrilintide dose (4.5 mg weekly) produced an average body-weight reduction of about 10.8%, compared with about 3% on placebo. About one in three people on the top dose lost at least 15% of their starting weight. Side effects were mostly stomach-related and matched what would be expected from this class of compound.

Research study

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Frias JP, Deenadayalan S, Erichsen L, et al. Lancet. 2023;402(10403):720–730. View source ↗

Scientific findings

This Phase 2 trial evaluated the combination of cagrilintide 2.4 mg plus semaglutide 2.4 mg ("CagriSema") once weekly versus semaglutide 2.4 mg alone and cagrilintide 2.4 mg alone in adults with type 2 diabetes inadequately controlled on metformin (with or without an SGLT2 inhibitor). At week 32, the mean change in HbA1c from baseline was greater with the combination than with cagrilintide alone, and the mean change in body weight was greater with the combination than with either monotherapy. The safety profile of the combination was broadly consistent with the individual components, with gastrointestinal events the most frequently reported adverse events.

Plain English

Researchers compared a weekly combination of cagrilintide plus semaglutide to each of the two compounds given alone, in adults with type 2 diabetes whose blood sugar wasn't well controlled on metformin. After 32 weeks, the combination produced larger reductions in average blood sugar (HbA1c) and larger body-weight reductions than either compound on its own. Side effects were mostly stomach-related, similar to either compound alone.

Storage & handling

Lyophilized: Store at -20°C, protected from light. Stable for 24+ months.

Reconstituted: Bacteriostatic water. Store reconstituted solution at 2–8°C and use within 28 days. Do not freeze.

Vial format: 10 mg lyophilized, vacuum-sealed glass vial.

Shipping: Lyophilized GLP-1 C is stable at ambient temperature for the typical 1–3 day shipping window. Cold-pack shipping available on request.

Frequently asked questions

What is GLP-1 C?+

GLP-1 C is the research code NovaWell uses for the molecule known in the published literature as Cagrilintide. It is a 37-amino-acid amylin analog and non-selective agonist at the amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor. It is built on a pramlintide-like backbone with substitutions that improve receptor affinity and stability, and it carries an N-terminal lysine acylation with a C20 fatty diacid via a γ-glutamic acid linker. That lipidation promotes reversible albumin binding and supports a multi-day plasma half-life consistent with once-weekly subcutaneous dosing in clinical-research settings.

How is amylin signaling different from GLP-1 signaling?+

Amylin and GLP-1 are distinct gut-and-pancreatic hormones acting through different receptor families. Amylin signals via the amylin receptor complexes — heterodimers of the calcitonin receptor with receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3) forming AMY1R, AMY2R, and AMY3R — and influences gastric emptying, glucagon secretion, and central satiety pathways. GLP-1 signals via the GLP-1 receptor and modulates glucose-dependent insulin release, glucagon suppression, and central appetite circuits. Because the receptor systems are non-overlapping, agonists of each pathway are being investigated together in metabolic research.

What is the rationale for combining GLP-1 C with GLP-1 S?+

The combination — referred to in published literature as "CagriSema" — pairs a long-acting amylin receptor agonist with a long-acting GLP-1 receptor agonist. Because the two compounds act on distinct receptor systems, the combination has been studied as a way to engage complementary satiety and glucose-regulatory pathways with a shared once-weekly dosing cadence. Published Phase 2 results in type 2 diabetes (Frias et al., Lancet 2023) reported greater HbA1c and body-weight changes with the combination than with either component alone over 32 weeks.

What does NovaWell test GLP-1 C for?+

Identity and purity by HPLC and mass spectrometry, bacterial endotoxin per USP <85>, heavy metals per USP, and sterility per USP. The COA for the current batch is in the Certificates tab.

How is GLP-1 C reconstituted and stored?+

For laboratory research, GLP-1 C is typically reconstituted with bacteriostatic water at a concentration suited to the research protocol. The lyophilized powder is stored at -20°C and protected from light; the reconstituted solution should be refrigerated at 2–8°C and used within 28 days. Avoid freeze–thaw cycles of the reconstituted material.

Where does NovaWell source GLP-1 C?+

GLP-1 C is synthesized by a contract manufacturer to NovaWell specifications and released only after third-party identity, purity, endotoxin, and sterility testing. Each lot ships with a batch-specific Certificate of Analysis; the COA for the currently shipping batch is in the Certificates tab. Recent batches have tested at 99%+ pure.